You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, January 2018
|
| DOI | 10.1186/s40425-017-0310-x |
| Pubmed ID | |
| Authors |
Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy, Paul Nghiem |
X Demographics
The data shown below were collected from the profiles of 33 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 16 | 48% |
| France | 1 | 3% |
| Australia | 1 | 3% |
| Brazil | 1 | 3% |
| Canada | 1 | 3% |
| Netherlands | 1 | 3% |
| New Zealand | 1 | 3% |
| Chile | 1 | 3% |
| Spain | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 9 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 21 | 64% |
| Scientists | 5 | 15% |
| Practitioners (doctors, other healthcare professionals) | 5 | 15% |
| Science communicators (journalists, bloggers, editors) | 2 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 190 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 190 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 20 | 11% |
| Researcher | 20 | 11% |
| Student > Master | 18 | 9% |
| Student > Ph. D. Student | 16 | 8% |
| Student > Postgraduate | 16 | 8% |
| Other | 37 | 19% |
| Unknown | 63 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 66 | 35% |
| Biochemistry, Genetics and Molecular Biology | 16 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 13 | 7% |
| Nursing and Health Professions | 7 | 4% |
| Immunology and Microbiology | 5 | 3% |
| Other | 14 | 7% |
| Unknown | 69 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 July 2023.
All research outputs
#1,101,494
of 26,017,215 outputs
Outputs from Journal for Immunotherapy of Cancer
#251
of 3,487 outputs
Outputs of similar age
#25,515
of 456,834 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#3
of 26 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,487 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 456,834 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.